Drug Database
IN

Integra Artificial Skin

✓ Approved

Integra LifeSciences · 治疗药物

什么是 Integra Artificial Skin?

Integra Artificial Skin 是一种治疗药物,由Integra LifeSciences研发。该药已获批,用于治疗相关适应症,给药途径:Others。

药物档案

公司Integra LifeSciences
给药途径Others
状态Approved

治疗适应症

Integra Artificial Skin 针对 3 个适应症,涉及 3 个治疗领域。

治疗领域疾病/病症分期
General disorders and administration site conditionsImpaired healing✓ Approved
Injury, poisoning and procedural complicationsThermal burn✓ Approved
Surgical and medical proceduresAdjuvant therapy✓ Approved

相关研究文献

PubMedNPJ digital medicine2026-11-19

Intersectional fairness in vision-language models for medical image disease classification.

Zhang Yupeng Y, Dunn Adam G AG, Naseem Usman U, Kim Jinman J

Medical artificial intelligence (AI) systems, particularly multimodal vision-language models (VLM), often exhibit intersectional biases, with models systematically less confident in diagnosing marginalised patient subgroups and producing higher rates of missed diagnoses. Current fairness interventions frequently fail to address these gaps or compromise overall diagnostic performance to achieve statistical parity. In this study, we developed Cross-Modal Alignment Consistency (CMAC-MMD), a training framework that standardises diagnostic certainty across intersectional patient subgroups without requiring sensitive demographic data during clinical inference. We evaluated this approach using 10,015 skin lesion images (HAM10000) with external validation on 12,000 images (BCN20000), and 10,000 fundus images for glaucoma detection (Harvard-FairVLMed), stratifying performance by intersectional age, gender, and race attributes. In the dermatology cohort, the proposed method reduced the overall intersectional missed diagnosis gap (difference in True Positive Rate, ΔTPR) from 0.50 to 0.26 while improving the Area Under the Curve (AUC) from 0.94 to 0.97 compared to standard training. Similarly, for glaucoma screening, the method reduced ΔTPR from 0.41 to 0.31, achieving a better AUC of 0.72 (vs. 0.71 baseline). This provides a methodological foundation toward clinical decision support systems that are both accurate and perform more equitably across diverse patient subgroups, without increasing privacy risks during inference.

PMID 43052422
阅读全文 →
PubMedInternational wound journal2026-11-19

Non-Pressure Skin Failure in Critically Ill Adults: Applying the Newly Updated NPIAP Definition to Assess Incidence, Risk Factors and Predictive Tools. A Prospective Cohort Study.

Bai Lihua L, Long Qingxiu Q, Zhu Xiuli X, Luo Zhenyu Z et al.

National Pressure Injury Advisory Panel defined non-pressure skin failure in August 2024. This study examined incidence, risk factors, and admission assessment tools under this definition. This prospective cohort study enrolled critically ill adults in two tertiary intensive care units from November 2024 to March 2025. Non-pressure skin failure was adjudicated by wound care specialists using National Pressure Injury Advisory Panel criteria, including daily examination and exclusion of pressure injury and other aetiologies. The Braden, Braden QD, Skin Mottling Score and Skin Failure Clinical Indicator Scale were assessed at admission. Multivariable logistic regression identified independently associated factors, and receiver operating characteristic analysis evaluated discriminative ability. Among 291 patients, 31 developed non-pressure skin failure, with an incidence of 10.65%. Decreased urine output, multiple vasoactive drugs and elevated arterial lactate were independently associated early post-admission factors. The Braden scale had the highest apparent area under the curve at 0.8088, followed by Braden QD, Skin Mottling Score and Skin Failure Clinical Indicator Scale. Positive predictive values were low across all tools. Decreased urine output, multiple vasoactive drugs and elevated arterial lactate were independently associated early post-admission factors. The Braden scale showed the highest apparent AUC among the four tools, although the DeLong test did not show a statistically significant difference between Braden and Braden QD (p = 0.412); low positive predictive values and lack of external validation limit the standalone utility of all tools.

PMID 43052684
阅读全文 →
PubMedJournal of imaging informatics in medicine2026-11-19

Correction: Artificial Intelligence in Orthopedic Image Analysis: A Systematic Review and Unified Taxonomy of Bone Age Assessment and Fracture Detection.

Liza Sumyia Sabrin SS, Tabib Md Arham MA, Bijoy Md Hasan Imam MHI, Hasan Md Zahid MZ et al.

PMID 43052639
阅读全文 →
PubMedDermatology (Basel, Switzerland)2026-11-19

The Skin and Gut Microbiome in Hidradenitis Suppurativa.

Gupta Aditya K AK, Liddy Amanda A, Saunte Ditte Marie L DML, Piguet Vincent V et al.

Recent evidence indicates that both the bacterial composition of the skin and gut microbiota may contribute to the pathogenesis and progression of hidradenitis suppurativa (HS). Several studies have identified differences in the skin bacterial microbiota of patients with HS compared with individuals without HS, as well as between lesional and non-lesional skin among patients with HS. These differences include an increased abundance of anaerobic taxa such as Prevotella and Porphyromonas, alongside a reduction in commensal taxa such as Cutibacterium, which may contribute to chronic inflammation and biofilm formation. Comparative analyses of HS lesional versus non-lesional skin have also revealed enrichment of bacterial pathways related to cell growth, DNA replication, and mismatch repair, suggesting enhanced microbial proliferation within HS lesions. Emerging evidence further suggests the presence of bacterial gut dysbiosis in HS, with some studies reporting reduced microbial diversity and lower abundance of protective genera Ruminococcaceae and Lachnospiraceae families. Efforts to modulate the skin and gut microbiota in HS are underway, exploring approaches such as dietary modification, antibiotic usage, and probiotic supplementation. The skin and gut microbiota may contribute to HS pathogenesis through alterations in microbial composition, microbial function, and interactions with systemic inflammation. However, current research remains fragmented, with small sample sizes, heterogeneous study designs, and a scarcity of robust interventional data. Further research is needed to clarify the role of microbiota in HS and determine whether microbiome-targeted interventions can improve disease outcomes.

PMID 43053655
阅读全文 →
PubMedMethods in molecular biology (Clifton, N.J.)2026-11-19

The Transformative Role of Artificial Intelligence in Wearable Health Monitoring: Applications in Diagnosis, Therapy, and Rehabilitation.

Shen Xiangru X, Luo Xuefeng X, Sun Yinsong Y, Zhu Zhenglin Z et al.

This chapter explores the transformative impact of artificial intelligence (AI)-augmented wearable technology in dynamic health monitoring across diagnosis, treatment, and rehabilitation. Innovations include real-time cardiovascular disease detection, AI-driven continuous glucose monitoring for diabetes, and neurological disorder tracking using flexible electroencephalograph (EEG) sensors. Therapeutic advances feature smart drug-delivery patches responsive to biomarkers, remote intervention systems, and surgical tools like augmented reality (AR) navigation. Rehabilitation breakthroughs encompass wearables for motor recovery, cardiopulmonary optimization, and neurorehabilitation using brain-computer interfaces. Future progress hinges on multifunctional hardware, federated learning for privacy, explainable AI, and standardized regulations.

PMID 43052671
阅读全文 →
PubMedNature2026-11-19

A glucose-powered artificial neuroimmune axis for metabolic control.

Xiu Weijun W, Wang Qian Q, Wan Ling L, Liang Zhuoming Z et al.

Metabolic disorders such as diabetes mellitus are global health crises driven by metabolic imbalance, chronic inflammation and dysfunction of the neuroimmune axis1-3. Electroceuticals targeting the autonomic nervous system have shown anti-inflammatory effects, yet existing systems lack the metabolic interoceptive feedback to fully restore immune-metabolic homeostasis4-9. Here we report an artificial neuroimmune axis (NeuroAxis) as a closed-loop immunomodulatory therapy for treating metabolic diseases. Analogous to its biological counterpart, NeuroAxis is solely powered by endogenous glucose, operating without batteries or wireless power transfer. It emulates the vagal reflex through closed-loop neuromodulation with metabolic interoceptive feedback. In a rat model of type 1 diabetes, NeuroAxis promotes the recovery of insulin-producing pancreatic β-cells and reduces inflammatory immune responses; in a rat model of type 2 diabetes, it drives macrophage remodelling and reduces systemic chronic inflammation. In both models, NeuroAxis restores glucose tolerance, improves insulin sensitivity and normalizes glycaemic control, with therapeutic effects persisting after treatment cessation. Our artificial neuroimmune axis promotes substantial advances in treating metabolic disorders and represents a general approach for autonomously regulating interorgan communication, central to homeostasis and pathophysiology.

PMID 43052470
阅读全文 →

注册免费账户还可查看另外 9996 篇文献

免费注册查看全部文献 →

了解更多Integra Artificial Skin